Latest News and Press Releases

La Phase 2b de l’étude SunRISe-1 montre un taux de réponse complète (RC) de 82 pour cent chez les patients, dont plus de la moitié des répondeurs ne présentent plus de cancer un an après la RC1 Ces...

Die Phase 2b-Studie SunRISe-1 zeigt, dass mehr als 82 Prozent der Patienten ein komplettes Ansprechen (CR) erreichten und mehr als die Hälfte der Responder ein Jahr nach dem CR krebsfrei blieben1 ...

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients...

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1 Results reinforce...

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic...

Nello studio pivotale Vivacity-MG3 e nella sua fase di estensione in aperto, nuovi e convincenti risultati dimostrano una riduzione costante degli anticorpi di tipo immunoglobuline G e un...

Die subkutane (SC) Verabreichung von amivantamab bietet den Patienten mehr Komfort, da sich die Verabreichungszeit von Stunden auf Minuten verkürzt und die Zahl der infusionsbedingten Reaktionen im...

Cet approbation renforce l’utilisation du daratumumab en traitement fondamental chez les patients atteints d’un myélome multiple nouvellement diagnostiqué, en faisant ainsi le seul anticorps anti-CD38...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...